[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"HALEON\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":129},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,64,86,107],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100643561","phase-1-a-study-to-evaluate-ibuprofen-ibu-625-mg-and-acetaminophen-apap-125-mg5-ml-in-an-oral-liquid-suspension-fixed-dose-combination-product-in-children-aged-6-to-11-years-100643561",false,"NCT07632274","A Study to Evaluate Ibuprofen (IBU) 62.5 mg and Acetaminophen (APAP) 125 mg\u002F5 ml in an Oral Liquid Suspension Fixed-Dose Combination Product in Children Aged 6 to 11 Years","A Phase I, Single-Center, Open-Label, Single-Dose, Pharmacokinetic Study to Evaluate Ibuprofen (IBU) 62.5 mg and Acetaminophen (APAP) 125 mg\u002F5 ml in an Oral Liquid Suspension Fixed-Dose Combination Product in Children Aged 6 to 11 Years","Inclusion Criteria:\n\n* Participants meeting at least one of the following criteria:\n\n  1. Participant with at least one acute, painful condition (e.g., minor aches and pains due to headache, menstruation, toothache, sports injuries, etc.) requiring use of an oral over the counter (OTC) analgesic within the previous 4 weeks (but not within the 48 hours prior to Day 1, Hour 0 investigational product dosing).\n  2. Participant has undergone a non-surgical orthodontic or dental procedure (e.g., placement of an orthodontic appliance or adjustment of braces) within 24 hours prior to dosing.\n  3. Participant with post-vaccination pain (post-injection site redness\u002Fsoreness, joint pain) and\u002For fever at time of investigational product dosing.\n  4. Participants who have a fever at time of investigational product dosing can be enrolled as long as the fever is low-grade (oral temperature less than (\\\u003C) 37.7 degree Celsius (°C) \u002F100.9 degrees Fahrenheit (ºF)) and, regardless of temperature, the fever has not lasted for more than (\\>) 48 hours as determined by the Investigator.\n* Participants except for medical condition(s) indicating the use of an OTC analgesic or post-immunization pain and\u002For fever, participants are in normal health as judged by the Investigator upon physical examination of the participant.\n* Participants\u002Fparent(s)\u002Flegal guardian who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.\n* Participants capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent document and in this protocol. A personally signed and dated informed consent document indicates that the child's parent(s)\u002Flegal guardian has been informed of all pertinent aspects of the study.\n* Participants with evidence of a personally signed (printed name is acceptable) and dated assent document or verbal assent, indicating the participant is willing to participate in the study. If assent is evaluated not to be obtainable, age and maturity appropriate information should be given verbally to the participants, and the Investigator should document the discussion.\n* Participants who are within the 5th and 95th percentiles in physical growth characteristics (i.e., height and weight) by sex as described by the Center for Disease Control and Prevention (CDC) standard growth charts, and body mass index (BMI) based on age and sex.\n* Participants must have a total body weight between 48-95 lbs (21.8-43.1 kilogram (kg)).\n\nExclusion Criteria:\n\n* Participants with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).\n* Participants with any condition or history felt by the Investigator to place the child at risk.\n* Participants with history of angioedema and bronchospastic reactivity to aspirin or other non-steroidal anti-inflammatory drug (NSAID).\n* Participants with known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients: Ibuprofen, or any other NSAID such as aspirin or naproxen, acetaminophen (paracetamol), or topical anesthetics (e.g., EMLA® cream).\n* Participants with use of antibiotic therapy within 14 days prior to Day 1.\n* Participants using the following:\n\n  1. Ibuprofen, or any other NSAID such as aspirin or naproxen, or acetaminophen (paracetamol) within 48 hours prior to dosing with investigational product.\n  2. Other prescription or nonprescription drugs within 2 weeks or 10 half-lives (whichever is longer) prior to dosing with investigational product.\n  3. Dietary and herbal supplements within 2 weeks prior to the first dose of investigational product and continuing through the last PK sample on Day 1.\n* Participants on treatment with an investigational drug within 90 days (or as determined by the local requirement) or 10 half-lives preceding the first dose of investigational product (whichever is longer).\n* Participants who has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days prior to signing the Informed Consent Form (ICF)\u002Fassent and\u002For during study participation.\n* Fever of greater than 38.3°C or if the participant is too ill to participate in the study, at screening and Day 1\u002FDay 1 of the study.\n* Screening supine systolic or diastolic blood pressure (BP) at or above the 90th percentile based on age and height percentiles (by sex) following at least 5 minutes of supine rest.\n* Participants with any laboratory result outside of the normal age-appropriate range that is judged by the Investigator to be clinically significant.\n* Participants with a positive urine drug screen.\n* Investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the Investigator, or Haleon employees, including their family members, directly involved in the conduct of the study.\n* Blood withdrawal as part of research or routine medical care, within 8 weeks of admission to the study site that would exceed 1.36 mL\u002Flbs per 8 weeks period, inclusive of medical care and planned sample collection for this study.\n* Participants with history of sensitivity to heparin or heparin-induced thrombocytopenia.\n* Participants with poor venous access.\n* Participants or participant parent(s)\u002Fguardians unwilling or unable to comply with the requirements of the protocol.\n* Participants who ate or drank grapefruit or grapefruit-related citrus fruits (e.g., Seville oranges, pomelos) from 2 weeks prior to dosing until collection of the final PK blood sample will be excluded as it could interfere with acetaminophen disposition.\n* Pregnant female participants of childbearing potential and at risk for pregnancy who are unwilling or unable to agree to an acceptable method of contraception for at least 5 weeks prior to the start of the trial, during the trial and for at least 30 days after the last dose of the investigational product.\n* Participants with history of substance abuse.",true,"ALL","6 Years","11 Years",{"count":21,"type":22},12,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The purpose of this study will be to characterize the pharmacokinetic (PK) profile of the Fixed-Dose Combination (FDC) IBU 62.5 milligram (mg)\u002FAPAP 125 mg per 5 milliliter (mL) suspension in children 6 to 11 years of age, inclusive, to satisfy Pediatric Research Equity Act (PREA) requirements.",[28],"Pain","RECRUITING","2026-06-29",{"date":32,"type":33},"2026-06-30","ACTUAL",{"date":35,"type":33},"2026-06-19",{"date":37,"type":22},"2026-09",{"name":39,"class":40},"HALEON","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":41},"100618860","a-study-evaluating-oral-health-related-quality-of-life-and-treatment-patterns-among-dentin-hypersensitivity-sufferers-100618860","NCT07337109","A Study Evaluating Oral-Health-Related Quality of Life and Treatment Patterns Among Dentin Hypersensitivity Sufferers","A Longitudinal Study Evaluating Oral-Health-Related Quality of Life and Treatment Patterns Among Dentin Hypersensitivity Sufferers in the Real World","Inclusion Criteria:\n\n* Participant who has provided consent indicating they have been informed of all pertinent aspects of the study.\n* All genders who, at the time of screening, are aged more than or equal to (\\>=)18 years.\n* Anyone who has begun to experience dentin hypersensitivity (self-reported) within the past three months.\n* Anyone who has started to use products to treat their tooth sensitivity within the past three months.\n* Participant who is able to independently complete all activities online.\n* Participants residing in the United States.\n\nExclusion Criteria:\n\n* Anyone who has any chronic health conditions that could impact their participation in this study, such as cancer, mental health disorders, history of serious illness in the last three months, history of substance abuse, or planned surgery during the study period.\n* Participant whose sensitivity could be caused by other factors or clinical pathology than DH, as self-reported on the screening questionnaire, which include:\n\n  1. Anyone who suffers from tooth cavities, significant gum disease, cracked or fractured teeth, temporomandibular joint disease (TMD), or who has had tooth extractions or fillings within the last three months.\n  2. Anyone who wears braces (including Invisalign-like appliances) for treatment or dentures (full or partial).\n  3. Participant who has undergone treatment for periodontal or gum disease within 6 months of screening or is currently undergoing treatment for periodontal or gum disease.\n  4. Participant who has been informed by a Dental Health Care Professional (DHCP) that they have active periodontitis.\n  5. Participant who has been informed by a DHCP that they have active caries.\n  6. Participant with any chronic and\u002For severe painful health condition(s) which lead to regular use of pain relief medications (more than 3 days a week).\n* Anyone who has participated in another dentin hypersensitivity study within the last three months.\n* Currently participating in another research study or will be participating in any other research study at any point during this study's duration.","18 Years",{"count":51,"type":22},375,"OBSERVATIONAL","The primary purpose of this study is to characterize changes in Oral-Health-Related Quality of Life (OHrQoL), as measured by the Dentin Hypersensitivity Experience Questionnaire (DHEQ) over a 12-month period.",[55],"Dentin Hypersensitivity","2026-04-27",{"date":58,"type":33},"2026-04-28",{"date":60,"type":33},"2025-12-16",{"date":62,"type":22},"2027-02",{"name":39,"class":40},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":16,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":23,"phases":73,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":41},"100631091","a-clinical-study-to-assess-the-effectiveness-of-use-of-three-experimental-denture-adhesives-compared-to-using-no-adhesive-100631091","NCT07496164","A Clinical Study to Assess the Effectiveness of Use of Three Experimental Denture Adhesives Compared to Using No-Adhesive","A Randomized, Controlled, Single-Blind, Cross Over Clinical Study Assessing the Maximum Maxillary Bite Force When Using Three Denture Adhesives Compared to Using No-Adhesive","Inclusion Criteria:\n\n* Participant provision of a signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed.\n* A male or female participant who, at the time of screening, is aged 18+ years.\n* A participant who is willing and able to comply with scheduled visits, and other study procedures.\n* A participant in good general and mental health with, in the opinion of the investigator or medically qualified designee, no clinically significant or relevant abnormalities in medical history or upon oral examination, or condition, that would impact the participant's safety, wellbeing or the outcome of the study, if they were to participate in the study, or affect the individual's ability to understand and follow study procedures and requirements.\n* A participant with a completely edentulous maxillary arch restored with a conventional maxillary full denture with an acrylic base.\n* A participant who is dentate in the mandibular arch or has a partial or full denture in the mandibular arch that is:\n\n  1. sufficiently stable, in the opinion of the investigator, to enable the bite force determination to be performed.\n  2. well made (according to the well-made assessment).\n\nExclusion Criteria:\n\n* A participant who is an employee of the investigational site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or a Haleon employee directly involved in the conduct of the study or a member of their immediate family.\n* A participant who has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days prior to Visit 1 and\u002For during study participation.\n* A participant who is pregnant (self-reported) or intending to become pregnant or who is breastfeeding over the duration of the study.\n* A participant with known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.\n* A participant unwilling or unable to comply with the Lifestyle Considerations described in this protocol.\n* A participant who is currently taking or has taken a bisphosphonate drug.\n* A participant who uses any medication or has a condition that, in the opinion of the investigator, would interfere with the conduct of the study.\n* A participant with a recent history (within the last year) of alcohol or other substance abuse.\n* A participant who has previously been enrolled in this study.\n* A participant who, in the opinion of the investigator, is unable to comply with study requirements and\u002For who is not able to reliably perform a valid bite.\n* A participant who, in the opinion of the investigator or medically qualified designee, should not participate in the study.",{"count":72,"type":22},60,[74],"NA","The aim of the proposed clinical study is to investigate the efficacy of three experimental denture adhesive creams to improve denture hold over a period of 13 hours.",[77],"Denture Retention","2026-04-06",{"date":80,"type":33},"2026-04-09",{"date":82,"type":33},"2026-03-30",{"date":84,"type":22},"2026-11",{"name":39,"class":40},{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":16,"sex":17,"minAge":49,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":106,"locationsCount":41},"100616048","real-world-study-of-a-calcium-sodium-phosphosilicate-anti-sensitivity-toothpaste-for-dentin-hypersensitivity-relief-100616048","NCT07300540","Real-World Study of a Calcium Sodium Phosphosilicate Anti-Sensitivity Toothpaste for Dentin Hypersensitivity Relief","A Real-World Evidence Study Evaluating Oral Health Related Quality of Life With Use of a Calcium Sodium Phosphosilicate Anti-Sensitivity Dentifrice for Dentin Hypersensitivity Management","Inclusion Criteria:\n\n* Participant who has provided consent indicating they have been informed of all pertinent aspects of the study.\n* All genders who, at the time of screening, are aged 18 to 65.\n* Participant who is able to independently complete all activities on their smart devices\n* Participant who has tooth sensitivity (self-reported symptoms).\n\nExclusion Criteria:\n\n* Participants whose tooth sensitivity could be caused by other factors or clinical pathology than DH, as self-reported on the screening questionnaire, which include:\n\n  1. Participant who has been\u002Fis on multiple prescription medications to treat severe acid reflux on a regular basis or has had surgery for acid reflux.\n  2. Participant with full or partial denture.\n  3. Participant who has undergone treatment for periodontal or gum disease within 6 months of screening or is currently undergoing treatment for periodontal or gum disease.\n  4. Participant who has been informed by a Dental Health Care Professional (DHCP) that they have active periodontitis.\n  5. Participants who have been informed by a DHCP that they have active caries.\n  6. Participant with any chronic and\u002For severe painful health condition which lead to regular use of pain relief medications (more than 3 days a week).\n* Participant with known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.","65 Years",{"count":95,"type":22},500,[74],"The aim of this study is to evaluate the impact of a commercially available desensitizing dentifrice containing 5 percent (%) Calcium sodium phosphosilicate (CSPS) on oral health related quality of life (OHrQoL) in a DH (Dentin Hypersensitivity) population in a real-world setting.",[99],"Dentin Sensitivity","2026-03-09",{"date":102,"type":33},"2026-03-11",{"date":104,"type":33},"2026-03-04",{"date":84,"type":22},{"name":39,"class":40},{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":16,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":116,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":41},"100612550","a-clinical-study-to-evaluate-the-effectiveness-of-an-experimental-toothpaste-in-improving-gum-health-and-reducing-plaque-accumulation-100612550","NCT07255040","A Clinical Study to Evaluate the Effectiveness of an Experimental Toothpaste in Improving Gum Health and Reducing Plaque Accumulation","A 24-Week, Randomised, Controlled, Examiner-blind, Clinical Study to Evaluate the Efficacy of an Experimental Stannous Fluoride Dentifrice in Improving Gingival Health and Reducing Plaque Accumulation","Inclusion Criteria:\n\n* Participant provision of a signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed.\n* Participant is of either sex and any gender who, at the time of screening, is at least 18 years old, inclusive.\n* A participant who is willing and able to comply with scheduled visits, treatment plan and other study procedures.\n* A participant in good general and mental health with, in the opinion of the investigator or medically qualified designee, no clinically significant or relevant abnormalities in medical history or upon oral examination, or condition, that would impact the participant 's safety, wellbeing or the outcome of the study, if they were to participate in the study, or affect the individual's ability to understand and follow study procedures and requirements.\n\nExclusion Criteria:\n\n* A participant who is an employee of the investigational site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or a Haleon employee directly involved in the conduct of the study or a member of their immediate family.\n* A participant who has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days prior to study entry and\u002For during study participation.\n* A participant with, in the opinion of the investigator or medically qualified designee, an acute or chronic medical, psychiatric condition or laboratory abnormality or any other clinical serious or unstable conditions (example, cardiovascular diseases, diabetes, liver disorders, and kidney disorders) that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the participant inappropriate for entry into this study.\n* A female participant who is a pregnant (self-reported) or intending to become pregnant over the duration of the study or who is breastfeeding.\n* A participant with known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.\n* A participant unwilling or unable to comply with the Lifestyle Considerations described in this protocol.\n* A participant who is a current smoker or an ex-smoker (including vaping) who stopped within 6 months of Screening or who is using smokeless forms of tobacco (example, chewing tobacco, gutkha, pan containing tobacco, nicotine-based e-cigarettes).\n* A participant who is diagnosed with xerostomia or is taking any medication that in the view of the investigator is causing xerostomia.\n* A participant who has a medical condition which could have directly influenced gingival bleeding (example, type 2 diabetes) or who has a bleeding disorder that could have affected study outcomes and\u002For participant safety.\n* A participant who has a recent history (within the last year) of alcohol or other substance abuse.\n* A participant who has a severe oral condition (example, acute necrotizing ulcerative gingivitis or oral or peri-oral ulceration including herpetic lesions) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant\u002Fexaminer if they participate in the study.\n* Presence of a tongue or lip piercing, or any other oral feature that could interfere with the usage of a toothbrush.\n* Dental Exclusions:\n\n  1. A participant who has active caries that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.\n  2. A participant who has dentures (partial or full).\n  3. A participant who has fixed orthodontic appliances or is undergoing active or recent (within 3 months of Screening) orthodontic treatment, which in the opinion of the investigator, could interfere with study procedures, assessments or outcomes.\n  4. A participant who has other orthodontic devices (example, bands, fixed retainers, or removable retainers) that could, in the opinion of the investigator, interfere with study procedures, assessment or outcomes.\n  5. A participant who has numerous restorations in a poor state of repair.\n  6. A participant who has any dental condition (example, overcrowding) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.\n  7. A participant who has had dental prophylaxis within 12 weeks of Screening.\n  8. A participant who has had teeth bleaching within 12 weeks of Screening.\n  9. A participant who has high levels of extrinsic stain or calculus deposits, in the opinion of the investigator, that could have interfered with plaque assessments.\n* A participant who has previously been enrolled in this study.\n* A participant who, in the opinion of the investigator or medically qualified designee, should not participate in the study.",{"count":115,"type":22},300,[74],"The aim of this 24-week clinical study is to evaluate the ability of an experimental dentifrice containing 0.454 percent (%) weight by weight (w\u002Fw) Stannous fluoride (SnF2); to improve gingival health, plaque reduction and prevention of plaque accumulation compared with a regular fluoride dentifrice (negative control) in participants with mild to moderate gingivitis.",[119,120],"Dental Plaque","Gingivitis","2025-12-12",{"date":123,"type":33},"2025-12-19",{"date":125,"type":33},"2025-11-19",{"date":127,"type":22},"2026-07",{"name":39,"class":40},""]